RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
RAPT Therapeutics (Nasdaq: RAPT), a clinical-stage biopharmaceutical company specializing in immunology-based therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Brian Wong, M.D., Ph.D., will deliver a company overview presentation on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.
The presentation will be accessible via live webcast, and an archived recording will be available on the company's investor relations website. RAPT Therapeutics focuses on developing novel treatments for patients with inflammatory and immunological diseases.
RAPT Therapeutics (Nasdaq: RAPT), una compagnia biofarmaceutica in fase clinica specializzata in terapie basate sull'immunologia, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan sulla Salute. Il Presidente e CEO della compagnia, Brian Wong, M.D., Ph.D., presenterà una panoramica dell'azienda giovedì 16 gennaio 2025, alle 9:00 ora del Pacifico.
La presentazione sarà accessibile tramite webcast dal vivo e una registrazione archiviata sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda. RAPT Therapeutics si concentra sullo sviluppo di nuovi trattamenti per i pazienti con malattie infiammatorie e immunologiche.
RAPT Therapeutics (Nasdaq: RAPT), una empresa biofarmacéutica en etapa clínica especializada en terapias basadas en inmunología, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan de Salud. El Presidente y CEO de la empresa, Brian Wong, M.D., Ph.D., realizará una presentación sobre la empresa el jueves 16 de enero de 2025, a las 9:00 a.m. hora del Pacífico.
La presentación será accesible a través de una transmisión en vivo, y se dispondrá de una grabación archivada en el sitio web de relaciones con inversores de la compañía. RAPT Therapeutics se enfoca en desarrollar tratamientos innovadores para pacientes con enfermedades inflamatorias e inmunológicas.
RAPT Therapeutics (Nasdaq: RAPT)는 면역학 기반 치료를 전문으로 하는 임상 단계의 생명공학 회사로, 제43회 연례 JP모건 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 사장 겸 CEO인 Brian Wong, M.D., Ph.D.는 2025년 1월 16일 목요일 오전 9시(태평양 표준시)에 회사 개요 발표를 진행할 예정입니다.
발표는 실시간 웹캐스트를 통해 접근 가능하며, 아카이브된 녹화본은 회사의 투자자 관계 웹사이트에서 확인할 수 있습니다. RAPT Therapeutics는 염증성 및 면역학적 질환을 가진 환자를 위한 혁신적인 치료법 개발에 집중하고 있습니다.
RAPT Therapeutics (Nasdaq: RAPT), une entreprise bio-pharmaceutique en phase clinique spécialisée dans les thérapies basées sur l'immunologie, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan sur la Santé. Le Président et CEO de l'entreprise, Brian Wong, M.D., Ph.D., présentera une vue d'ensemble de l'entreprise jeudi 16 janvier 2025, à 9h00, heure du Pacifique.
La présentation sera accessible par webdiffusion en direct, et un enregistrement archivé sera disponible sur le site des relations investisseurs de l'entreprise. RAPT Therapeutics se concentre sur le développement de nouveaux traitements pour les patients atteints de maladies inflammatoires et immunologiques.
RAPT Therapeutics (Nasdaq: RAPT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf immunologische Therapien spezialisiert ist, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference bekannt gegeben. Der Präsident und CEO des Unternehmens, Brian Wong, M.D., Ph.D., wird am Donnerstag, den 16. Januar 2025, um 9:00 Uhr pazifischer Zeit eine Unternehmenspräsentation halten.
Die Präsentation wird über einen Live-Stream zugänglich sein, und eine aufgezeichnete Version wird auf der Investor Relations-Website des Unternehmens verfügbar sein. RAPT Therapeutics konzentriert sich auf die Entwicklung neuartiger Behandlungen für Patienten mit entzündlichen und immunologischen Erkrankungen.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time.
To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with inflammatory and immunological diseases. The company leverages its proprietary discovery and development platform to advance both biologics and selective small molecules aimed at normalizing critical immune drivers underlying these conditions.
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
FAQ
When is RAPT Therapeutics presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors access RAPT Therapeutics' J.P. Morgan Healthcare Conference presentation?
What is RAPT Therapeutics' current development focus?
Who will be presenting for RAPT Therapeutics at the 2025 J.P. Morgan Healthcare Conference?
